CHAIRS

Cheryl Ho, MD, FRCP(C)

Clinical Assistant Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Cheryl Ho is a clinical assistant professor at the University of British Columbia a medical oncologist at BC Cancer.

She is currently the provincial systemic chair for head and neck malignancies.

She completed medical school and internal medicine training at the University of Western Ontario.

She is a graduate of the BC Cancer Agency Medical Oncology program and completed a fellowship in Thoracic Oncology at University of California, Davis.

Her current practice focuses on the treatment of thoracic and head and neck malignancies.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Randeep Sangha, MD, FRCPC

Medical Oncologist, Cross Cancer Institute
Associate Professor, University of Alberta
Edmonton, AB

Dr. Sangha is an Associate Professor in the Department of Oncology at the University of Alberta and Medical Oncologist at the Cross Cancer Institute, Edmonton, AB. He is the Provincial Lead for the Alberta Lung Cancer Program.

Dr. Sangha received his medical degree at the University of Alberta and subsequently specialized in Internal Medicine and Medical Oncology. He completed two years of post-fellowship training in thoracic oncology at the University of California, Davis Comprehensive Cancer Center.

His academic, clinical, and educational activities revolve around thoracic and hematological malignancies. He is also experienced in Investigational New Drug (Phase I) development and is actively involved in the Phase I clinical trials program at the Cross Cancer Institute.

Devin Schellenberg, MD, FRCS(C)

Clinical Associate Professor – UBC
Department Head, Radiation Oncology
BC Cancer – Surrey Centre

Dr. Devin Schellenberg is a radiation oncologist practicing at the BC Cancer Surrey Centre. He is currently the department head of radiation oncology at Surrey Centre and is one of the leaders in the British Columbia stereotactic radiation working group.

His radiation oncology residency was carried out at Princess Margaret Hospital in Toronto and the BC Cancer Agency, after which he completed a fellowship in stereotactic body radiation therapy at Stanford University in 2007.

His present research is focused on the use of novel imaging modalities in radiation therapy.

FACULTY

Justin Gainor, MD

Director, Center for Thoracic Cancers
Massachusetts General Hospital
Director of Targeted Immunotherapy
Henri & Belinda Termeer Center
Assistant Professor of Medicine at Harvard Medical School
Boston, MA

Dr. Justin Gainor is Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the DF/HCC Lung Cancer Program. His major research interests have centered around two themes: targeted therapy and immunotherapy. He is the principal investigator of multiple clinical trials evaluating novel targeted therapies among patients with oncogene-driven lung cancers, with a particular focus on oncogenic fusions involving anaplastic lymphoma kinase (ALK) and RET. Complementing these efforts, he also led efforts to define the molecular mechanisms of resistance to targeted therapies.

Recently, he worked to transfer the same clinical-translational research framework pioneered in targeted therapies to the immunotherapy setting. He is a co-leader of the SU2C/AACR/ACS Lung Cancer Dream Team, in which he is leading efforts to define determinants of response to checkpoint inhibitors. These translational studies are complemented by leading various phase I/II trials examining novel immunotherapy combinations.

His official titles are in the beginning of his bio. Additionally, he is an Assistant Professor of Medicine at Harvard Medical School.

Ella Kazerooni, MD, MS

Professor of Radiology & Internal Medicine
University of Michigan
Chair, National Lung Cancer Roundtable
Ann Arbor, MI

Dr. Kazerooni is a Professor of Radiology and Internal Medicine at the University of Michigan in Ann Arbor, Michigan. Specializing in cardiothoracic radiology, her academic focus is the development, validation and integration of advanced imaging technologies in cardiothoracic radiology into practice, from bench to beside. Partnering with basic science and clinical colleagues in radiology and pulmonary medicine, she is highly respected internationally for her expertise, and is an active contributor to multicenter multidisciplinary studies to further our understanding of quantitative imaging and disease phenotyping.

Her interest in screening led to serving as a site PI for NLST, and includes leading the development of LungRADS, the Designated Lung Cancer Screening Center program as part of the ACR CT accreditation program, and the ACR’s Lung Cancer Screening Registry.  She is honored to serve as the inaugural Chair of the National Lung Cancer Roundtable through the American Cancer Society – dedicated to creating lung cancer survivors by improving care across the lung cancer care continuum from early detection through treatment, to eliminating the stigma that clouds lung cancer patient care, and creating a public consciousness of hope for patients and families impacted by this leading cause of cancer death.

Yu Shyr, PhD

Harold L. Moses Chair in Cancer Research
Chairman, Department of Biostatistics
Director, Vanderbilt Center for Quantitative Sciences
Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD)
Professor of Biostatistics, Biomedical Informatics and Health Policy
Vanderbilt University Medical Center
Nashville, TN

Yu Shyr received his Ph.D. in biostatistics from the University of Michigan (Ann Arbor) in 1994 and subsequently joined the faculty at Vanderbilt University School of Medicine. Dr. Shyr is a Fellow of the American Statistical Association (ASA), an elected fellow of the American Association for the Advancement of Science (AAAS) and a US Food and Drug Administration (FDA) advisory committee voting member.

He has published more than 480 peer-reviewed papers in a variety of journals (h-index = 103). Dr. Shyr was the member of the US National Academy of Medicine (IOM) Committee on Policy Issues in the Clinical Development of Biomarkers for Molecularly Targeted Therapies. He has served as a member of the US National Cancer Institute (NCI) Developmental Therapeutics Study Section, Cancer Immunopathology and Immunotherapy Study Section and the Population and Patient-oriented Training Study Section. Dr. Shyr was the co-course director for the AACR/ASCO Methods in Clinical Cancer Research Vail Workshop. He is the Associate Editor for JAMA Oncology, Journal of Thoracic Oncology (JTO), and the Statistical Advisory Board Member for PLoS ONE.

In addition, Dr. Shyr is the principle investigator of the NCI U01 grant of Barrett’s esophagus translational research network coordinating center (BETRNetCC). Dr. Shyr’s current research interests focus on developing statistical bioinformatic methods for analyzing next-generation sequencing data based on single cell technology including a series of papers on estimating the sample size requirements for studies conducting sequencing analysis and novel statistical methods for analyzing the single-cell RNA sequencing (scRNA-seq) data.

Jonathan Spicer, BSc (Hon), MD, PhD, FRCS

Assistant Professor of Surgery
McGill University
Montreal, QC

Dr. Spicer was born and raised in Montreal and completed his Bachelor degree in Science at McGill University. He continued his medical training at McGill where he earned his MD, after which he moved to Vancouver and completed his surgical internship at the University of British Columbia. He returned to McGill the following year and completed his general surgical training during which he participated in the Surgeon Scientist and Clinical Investigator programs as an FRSQ funded student and earned a PhD in Experimental Surgery.

Dr. Spicer completed his training in Cardiothoracic Surgery at the world’s largest cancer center – University of Texas, MD Anderson Cancer Center in Houston. His clinical interests focus on minimally invasive approaches to lung cancer as well as complex resections for advanced thoracic malignancies. He has paired his clinical focus with a comprehensive research program in cancer metastasis. His laboratory studies the link between inflammation and metastasis with a particular focus on neutrophil and circulating tumor cell interactions.

James Welsh, MD

Associate Professor
Radiation Oncology Department
MD Anderson Cancer Center
Houston, TX

Dr. Welsh had a singular focus in life to help humanity, and during his college years he became intrigued by the power of the immune system and astonished that cancer cells could adapt by evading immune detection. This interest led to his first job at Genentech, where he witnessed the development of some of the first targeted therapies, including trastuzumab (Herceptin).

In his current position as a tenured Associate Professor at MD Anderson Cancer Center, Dr. Welsh realizes his mission on a daily basis. As an independent investigator, Dr. Welsh is now focused on enhancing the effects of immunotherapy through its rational combination with radiation. This work includes running many of the first trials of anti-CTLA-4 and anti-PD1 with radiation, as well as testing preclinical models of immunotherapy with radiation.

His lab recently developed the first mouse model of PD1 resistance and they actively investigate the mechanisms how cancer cells adapt to evade the immune system. Running a lab in addition to treating patients provides a unique clinical insight that comes from seeing firsthand how best to combine immunotherapies with radiation, with the ultimate goal of developing truly personalized therapeutic approaches.

Paul Wheatley-Price BSc, MBChB, FRCP (UK), MD

Associate Professor of Medicine, Div. of Medical Oncology
University of Ottawa
Medical Oncologist, The Ottawa Hospital Cancer Centre
Ottawa, ON

Dr Wheatley-Price is a medical oncologist at The Ottawa Hospital, with an academic appointment at the University of Ottawa. His research interests are in thoracic oncology, with an emphasis on systemic therapy in challenging clinical scenarios, and in the rare cancer types mesothelioma and thymoma.

He is active in lung cancer advocacy, in June 2016 becoming President of Lung Cancer Canada, a national charity supporting lung cancer patient and caregivers, and promoting advocacy and research.

At the Ottawa Hospital he is the clinical lead for lung cancer in the Division of Medical Oncology, and is the Deputy Division head.